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Background
In community public health antiretroviral therapy (ART)
programs, HIV-1 viremia in patients has been reduced
over the last decade through improved drug regimens,
adherence, and genotypic testing to manage ART. How-
ever, a large portion (up to 25%) of ART patients
remain viremic with risk of disease progression and
community-level transmission of drug resistance muta-
tions. We hypothesized that HIV-1 viral evolutionary
rate (vEvol) during incomplete suppression of HIV-1
RNA is associated with ART use, selection of drug resis-
tance, and viral load.
Methods
HIV-1 reverse transcriptase (RT) and protease (Pr)
sequences were obtained from 306 patients receiving
ART at San Mateo Medical Center (1997-2006). From
150 paired sequences in 75 viremic patients, vEvol was
determined using the TVM+I+G nucleotide substitution
model in PAUP. Resistance mutations and genotypic
susceptibilities to 19 ARV drugs were determined using
the HIVseq algorithm (HIVDB.stanford.edu) and drug
resistance mutations were correlated using hierarchical
agglomerative clustering analysis. Statistical analysis was
done in SAS v9.1.
Results
75 paired genotypes were a median of 10.9 months apart
with median CD4 cells 260/cu mm and geometric mean
RNA VL 3.94 log copies/mL. ART was RTI-based
(reverse-transcriptase inhibitor) in 38 (51%) vs. PI-based
(protease inhibitor) in 37 individuals (49%), with similar
rates of drug resistance mutations (89%) in either drug
class. Median vEvol was higher in those with PI- (but
not RTI) associated drug resistance mutations (p < 0.05,
Wilcoxon rank-sum [WRS]). Higher vEvol was asso-
ciated with reduced genotypic susceptibility scores to
nRTI, nnRTI, and PI drugs (p < 0.0001, Spearman rank
correlation). Hierarchical cluster analyses of all 306
sequences revealed many highly correlated drug resis-
tance mutation pairs including T215Y/M41L in RT,
V82/I54 in Pr, and M184V/L90M in RT/Pr, each being
associated with higher vEvol (p < 0.05, WRS).
Discussion
Repeated HIV-1 RNA genotyping in viremic patients
showed significant drug resistance mutations in 89% and
evolutionary changes in RT/Pr in approximately 75%.
Viral evolution was significantly greater among those
with higher HIV-1 VL, exposure to PI drugs and specific
patterns of resistance mutations. The accumulation of
drug resistance mutations in explicit patterns during
ART treatment is an evolutionary response to drug
selective pressure driven by virus replication.
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